MaxCyte $MXCT grew Q3 revenue 49% to $10.2M, with core revenue up 27% and about $2.0M from SPL programs. The net loss narrowed to $4.8M ($0.05/share) from $12.

MaxCyte $MXCT grew Q3 revenue 49% to $10.2M, with core revenue up 27% and about $2.0M from SPL programs. The net loss narrowed to $4.8M ($0.05/share) from $12.4M, and management raised full-year revenue guidance to at least $34.5M. It also announced a definitive agreement to acquire Akron Bio, sign…